PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Oct 30, 2020

byprotokinetixp

AAGP® | biotechnology | biotechnology investments | dry-eye | market opportunity

Biotech Investing: How to Pick a Winner

The promise of biotechnology stocks to the average investor is the potential for blazing growth and incredible returns. But not every company pays dividends on that promise. Too many times,...Read more

Sep 22, 2020

byprotokinetixp

dry-eye | Ocular inflammation

Dry Eye Disease: Investor Presentation

Dry eye disease (DED) is a multifactorial disease of the ocular surface which results in a spectrum of symptoms and/or signs that affect 5 30% of the population. Download our...Read more

Sep 21, 2020

byprotokinetixp

Seeking improved treatments for dry eye disease

A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including...Read more

Jul 07, 2020

bybhenderson

dry-eye

ProtoKinetix AAGP® Dry Eye Program Advancing

Marietta, Ohio, July 7, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye...Read more

Apr 06, 2020

bybhenderson

dry-eye

ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease

Marietta, Ohio, April 6, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, having recently announced filing for patent protection for new applications of...Read more

Mar 19, 2020

bybhenderson

dry-eye

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Marietta, Ohio, March 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule. During recent testing conducted by...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.